<DOC>
	<DOCNO>NCT01697709</DOCNO>
	<brief_summary>Despite benign public perception , marijuana use disorder represent significant public health problem . The development safe effective pharmacotherapies marijuana dependence important unmet public health need . Quetiapine , effective atypical antipsychotic act block serotonin type 2A , dopamine type 2 , histamine type 1 , adrenergic receptor , promise treatment substance use disorder . In animal model , quetiapine block enhancement reward cocaine , likely due action dopamine non-dopamine neurotransmission . Clinical study quetiapine show benefit treatment alcohol cocaine use disorder . Conceptually , clinically prominent effect quetiapine , namely sedation , anxiolysis , mood stabilization appetite stimulation , good match symptom marijuana withdrawal . Most importantly , open-label dose-finding study quetiapine treatment marijuana dependence conduct research group determine quetiapine well-tolerated associate reduction marijuana use indicate promise agent deserve study marijuana-dependent outpatient . The propose research project randomize double-blind placebo-controlled clinical trial evaluate efficacy quetiapine treatment marijuana dependence 12-week period . All participant receive Medical Management , medication adherence focus psychosocial intervention facilitates compliance study medication study procedure , promotes abstinence marijuana substance , encourage mutual-support group attendance . All participant receive voucher incentive compliance study visit attendance , return study medication bottle , complete study procedure , objective achieve highly compliant sample . The goal phase II clinical trial build promise open-label pilot study result examine efficacy quetiapine participant ' marijuana consumption placebo-controlled double-blind condition use abstinence-initiation model , participant use marijuana regularly study entry , reduce use , achieve abstinence . The specific aim project determine whether quetiapine superior placebo 1 ) reduce marijuana use 2 ) achieve abstinence .</brief_summary>
	<brief_title>Quetiapine Pharmacotherapy Cannabis Dependence</brief_title>
	<detailed_description>In 12-week randomized double-blind placebo-controlled clinical trial , evaluate efficacy quetiapine treatment marijuana dependence 150 outpatient . Participants randomly assign treatment double-blind condition either fixed dosing schedule quetiapine placebo . All participant receive Medical Management , medication adherence focus psychosocial intervention facilitates compliance study medication study procedure , promotes abstinence marijuana substance . All participant receive progressive voucher incentive compliance study visit attendance complete study procedure , objective achieve highly compliant sample . The result dose-finding pilot study quetiapine treatment marijuana dependence ( see Preliminary Studies ) suggest ideal dose propose project single 300 mg dose every evening , achieve gradual three-week titration . Clinical experience medication treatment marijuana dependence indicate gradual upward titration dose advisable maximize tolerability morning dose poorly tolerate . Quetiapine ( immediate release formulation ) administer 25 100 mg capsule ; placebo capsule appear identical quetiapine capsule . Participants treatment arm take number pill schedule . Study medication dispense weekly basis start baseline visit . Quetiapine titrate three-week period target dose 300 mg maximum tolerate dose . The research psychiatrist make dose reduction tolerability necessary .</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>1 . Meets DSMIVTR criterion current marijuana dependence 2 . Reports use marijuana average 5 day per week past 28 day 3 . Between age 18 60 4 . Able provide inform consent comply study procedures 5 . Seeking treatment cannabis dependence 1 . Lifetime DSMIV diagnosis schizophrenia , schizoaffective disorder , bipolar disorder . 2 . Current DSMIV criterion psychiatric disorder may , accord investigator 's judgment , require either pharmacological nonpharmacological intervention course study . 3 . Patients prescribed psychotropic medication . 4 . History allergic reaction , intolerance , hypersensitivity Quetiapine . 5 . Pregnancy , lactation , failure use adequate contraceptive method female patient currently engage sexual activity men . 6 . Unstable medical condition , poorly control hypertension might make participation hazardous . 7 . Diabetes ( whether control ) , meet criterion metabolic syndrome define NCEP ( 3 following : a. obesity [ waist circumference &gt; 40 inch ] , b. hyperglycemia [ fast glucose &gt; 100 mg/dl Rx ] , c. dyslipidemia [ TG &gt; 150 mg/dl Rx ] , d. dyslipidemia [ HDL cholesterol ; 40 mg/dl ( male ) , 50 mg/dl ( female ) Rx ] , e. hypertension [ 130 mmHg systolic &gt; 85 mmHg diastolic Rx ] . Participants BMI &gt; 35 exclude . 8 . Current DSMIV diagnosis alcohol substance use disorder ( abuse dependence ) marijuana nicotine dependence . 9 . Positive confirm result urine toxicology screen . 10 . Are legally mandate participate substance use disorder treatment program . 11 . Increased risk suicide . 12 . QTc prolongation ( screen electrocardiogram Qtc &gt; 450 msec men , QTc &gt; 470 msec woman ) history QTc prolongation use concomitant medication prolong QTc interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cannabis</keyword>
	<keyword>marijuana</keyword>
	<keyword>pharmacotherapy</keyword>
</DOC>